~~<i id='AEFD949C12'><strike id='AEFD949C12'><tt id='AEFD949C12'><pre id='AEFD949C12'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

hotspot

leisure time

author：Wikipedia 2025-10-01 15:31:06 - browse：38267

Damian Garde of STAT talks with Liisa Bayko of Evercore ISI and Jared Holz of Mizuho at STAT in NYC. — Damian Garde of STAT, left, talked with Liisa Bayko of Evercore ISI and Jared Holz of Mizuho about the GLP-1 weight loss market. Michelle C. Gevint for STAT

NEW YORK — Will the world actually soon spend $100 billion a year on the new obesity medicines?

Plenty of people in pharma and at the banks that invest in it seem to think so. Goldman Sachs, Barclays, BMO Capital Markets and Pfizer have all arrived at the glossy, cut-for-headline number for spending by around 2030.

Yet Jared Holz, a healthcare strategist at Mizuho, is skeptical.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： CRISPR pioneers react to Casgevy, first gene

hotspot

entertainment

focus

entertainment

hotspot

AdobeWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetourbiotechnewsletterinyo

WSS

The science behind Janet Jackson's pregnancy at 49

Anthos stroke drug appears safer than common blood thinner

With FDA staff opposed to Sarepta therapy, top official intervened

CDC concerned about possible undetected monkeypox spread in U.K.

New guidelines on severe brain injury complicate already difficult decisions

STAT's guide to the next generation of CAR

hotspot

leisure time

hotspot

Peter Hotez and the public health issue of online harassment

With FDA staff opposed to Sarepta therapy, top official intervened

Hollywood unions extend contract negotiations for actors

Does good food count as health care? Study aims to find out

Psychedelics group wrestles with new pharma identity

PBM reforms clear House panel

As demand for Covid shots wanes, Moderna seeks its next success

Death of patient in Alzheimer’s trial raises question of possible risks

After affirmative action ruling, medical educators look to 'holistic review'

Weight bias in eating disorder treatment complicated by new weight loss drugs

entertainment

Surge of respiratory disease in China has likely explanation

The science behind Janet Jackson's pregnancy at 49

PBM reforms clear House panel

Readout Newsletter: What is Casgevy? Does Wegovy hurt muscle?

Cloning humans is technically possible. It's curious no one has tried

Astellas still sees hope in its gene therapy after four deaths

entertainment

focus

entertainment

hotspot